| Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure AG Leach, HD Jones, DA Cosgrove, PW Kenny, L Ruston, P MacFaul, ... Journal of medicinal chemistry 49 (23), 6672-6682, 2006 | 310 | 2006 |
| Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally … M Addie, P Ballard, D Buttar, C Crafter, G Currie, BR Davies, J Debreczeni, ... Journal of medicinal chemistry 56 (5), 2059-2073, 2013 | 263 | 2013 |
| Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014 KG Pike, K Malagu, MG Hummersone, KA Menear, HME Duggan, ... Bioorganic & medicinal chemistry letters 23 (5), 1212-1216, 2013 | 251 | 2013 |
| Species differences in drug plasma protein binding N Colclough, L Ruston, JM Wood, PA MacFaul MedChemComm 5 (7), 963-967, 2014 | 64 | 2014 |
| Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent … Q Su, E Banks, G Bebernitz, K Bell, CF Borenstein, H Chen, CE Chuaqui, ... Journal of medicinal chemistry 63 (9), 4517-4527, 2020 | 56 | 2020 |
| Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1, 3, 4-oxadiazol-2-yl) pyrazin-2-yl)-1-ethyl-1, 2, 4-triazol-3-yl) piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and … B Barlaam, S Cosulich, B Delouvrié, R Ellston, M Fitzek, H Germain, ... Bioorganic & Medicinal Chemistry Letters 25 (22), 5155-5162, 2015 | 41 | 2015 |
| Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2 KG Pike, J Morris, L Ruston, SL Pass, R Greenwood, EJ Williams, ... Journal of Medicinal Chemistry 58 (5), 2326-2349, 2015 | 38 | 2015 |
| Activation energies for the decomposition of pharmaceuticals and their application to predicting hydrolytic stability in drug discovery PA MacFaul, L Ruston, JM Wood MedChemComm 2 (2), 140-142, 2011 | 35 | 2011 |
| IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling … A Ahmad, X Pepin, L Aarons, Y Wang, AS Darwich, JM Wood, ... European Journal of Pharmaceutics and Biopharmaceutics 156, 50-63, 2020 | 33 | 2020 |
| Discovery and optimization of a novel series of highly selective JAK1 kinase inhibitors NP Grimster, E Anderson, M Alimzhanov, G Bebernitz, K Bell, C Chuaqui, ... Journal of Medicinal Chemistry 61 (12), 5235-5244, 2018 | 26 | 2018 |
| Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26. 12, effective in oxaliplatin-induced peripheral neuropathy G Warren, M Osborn, C Tsantoulas, A David-Pereira, D Cohn, P Duffy, ... The Journal of Pain 25 (7), 104470, 2024 | 20 | 2024 |
| Determining bioequivalence possibilities of long acting injectables through population PK modelling P Gajjar, J Dickinson, H Dickinson, L Ruston, HB Mistry, C Patterson, ... European Journal of Pharmaceutical Sciences 179, 106296, 2022 | 14 | 2022 |
| Luminescence Screening Assays for the Identification of Sensitizers for Lanthanides Based on the Controlled Formation of Ternary Lanthanide Complexes with DTPA–Bisamide Ligands LL Ruston, GM Robertson, Z Pikramenou Chemistry–An Asian Journal 5 (3), 571-580, 2010 | 11 | 2010 |
| Discovery of the JAK1 selective kinase inhibitor AZD4205 JG Kettle, Q Su, N Grimster, S Kawatkar, S Throner, R Woessner, H Chen, ... Cancer Research 77 (13_Supplement), 979-979, 2017 | 10 | 2017 |
| Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold B Barlaam, S Cosulich, M Fitzek, S Green, CS Harris, K Hudson, ... Bioorganic & Medicinal Chemistry Letters 25 (13), 2679-2685, 2015 | 10 | 2015 |
| Aqueous solubility in drug discovery chemistry, DMPK, and biological assays N Colclough, L Ruston, K Tam Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and …, 2008 | 8 | 2008 |
| Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors B Barlaam, S Cosulich, M Fitzek, H Germain, S Green, LL Hanson, ... Bioorganic & Medicinal Chemistry Letters 27 (13), 3030-3035, 2017 | 7 | 2017 |
| Compounds and methods for inhibiting JAK A ASTRAND, N GRIMSTER, S KAWATKAR, JG Kettle, MK NILSSON, ... US Patent 10,167,276, 2019 | 6 | 2019 |
| The discovery of AZD4547: an orally bioavailable, potent and selective N-(5-Pyrazolyl) benzamide FGFR1-3 inhibitor AP Thomas, ME Theoclitou, D Buttar, L Ruston, G Wrigley, M Dennis, ... Cancer Research 72 (8_Supplement), 3912-3912, 2012 | 3 | 2012 |
| Compounds and methods for inhibiting JAK ABM ASTRAND, NP Grimster, S KAWATKAR, JG Kettle, MK NILSSON, ... US Patent 10,654,835, 2020 | 2 | 2020 |
